Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashkenazi, Moshe, Sity, Saray, Sarouk, Ifat, Bar Aluma, Bat El, Dagan, Adi, Bezalel, Yael, Bentur, Lea, De Boeck, Kris, Efrati, Ori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016275/
https://www.ncbi.nlm.nih.gov/pubmed/29950869
http://dx.doi.org/10.2147/JAA.S156049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016275/
https://www.ncbi.nlm.nih.gov/pubmed/29950869
http://dx.doi.org/10.2147/JAA.S156049

Ejemplares similares